Journals / İstanbul Medical Journal / 2019 / Cilt: 20 - Sayı: 1

The Importance of Computerized Drug Interaction Checker Programs Used in Community Pharmacies to Avoid Potential Drug Interactions: A Preliminary Study with Clarithromycin

Potansiyel İlaç Etkileşimlerinin Önlenmesinde Serbest Eczanelerde Kullanılan Bilgisayarlı İlaç Etkileşimi Kontrol Programlarının Önemi: Klaritromisin ile Yapılan Bir Ön Çalışma

Pages
67–71
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The use of this program in the communitypharmacies could minimize PDDIs during the dispensing ofmedicine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Drug-drug interactions (DDI) due to multiple druguse are the most important cause of adverse drug reactions.DDIs are among medication errors that can be prevented.
📊
Key Findings & Data:Theintegrated computerized drug interaction checker programs,which medical professionals use in addition to their medicaland practical knowledge, can help medical staff to reducepotential DDIs (PDDIs), although they are not sufficient alone.The aim of this study was to investigate the role of computerizeddrug interaction checker programs in the identification andprevention of PDDIs in clarithromycin prescribed pediatricoutpatients.Methods: The study was a retrospective observational prescriptionanalysis held in three community pharmacies operating in theprovince of Üsküdar-İstanbul during 12-month period.
💡
Conclusion & Impact:The use of this program in the communitypharmacies could minimize PDDIs during the dispensing ofmedicine.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Drug-drug interactions (DDI) due to multiple druguse are the most important cause of adverse drug reactions.DDIs are among medication errors that can be prevented. Theintegrated computerized drug interaction checker programs,which medical professionals use in addition to their medicaland practical knowledge, can help medical staff to reducepotential DDIs (PDDIs), although they are not sufficient alone.The aim of this study was to investigate the role of computerizeddrug interaction checker programs in the identification andprevention of PDDIs in clarithromycin prescribed pediatricoutpatients.Methods: The study was a retrospective observational prescriptionanalysis held in three community pharmacies operating in theprovince of Üsküdar-İstanbul during 12-month period. Theprescriptions with oral clarithromycin medication were selectedand PDDIs were analyzed using the RxMediaPharma® softwareon an active substance base.Results: During the 12-month period, 100 prescriptionscontaining 266 medicines were prescribed by 52 differentphysicians. The mean number of medicines per prescription was2.66±1.11. Of the 16 PDDIs detected, five were clarithromycinrelated(31.25%) and 11 were non-clarithromycin-related(68.75%). When PDDIs were categorized by severity, 10 out of 16(62.5%) were high-risk, two (12.5%) were moderate and four (25%)were low-risk. Clarithromycin interactions were moderate withlidocaine and low with both metronidazole and sultamicillin(ampicillin/sulbactam).Conclusion: Although evidence based computerized druginteraction checker programs that provide rapid access is notsufficient alone, they can help health care professionals inpreventing PDDIs. The use of this program in the communitypharmacies could minimize PDDIs during the dispensing ofmedicine.

Özet

Amaç: Çoklu ilaç kullanımına bağlı olarak gelişen ilaç-ilaç etkileşimleri (DDI) advers ilaç reaksiyonlarının en önemli nedenidir. İlaç hatalarından bir tanesi olarak sayılan DDI önlenebilir. Sağlık profesyonellerinin tıbbi ve pratik bilgilerinin yanında kullanacakları entegre bilgisayarlı ilaç etkileşimi kontrol sistemleri, tek başlarına yeterli olmamakla beraber olası etkileşimlerin azaltılması için sağlık personeline yardımcı olabilir. Bu çalışmada ayaktan pediatri hastalarına reçete edilen klaritromisin ile potansiyel DDI’ların (PDDI) belirlenmesi ve önlenmesinde bilgisayarlı ilaç etkileşimi kontrol sistemlerinin rolünün araştırılması amaçlanmıştır. Yöntemler: Retrospektif gözlemsel reçete analizi niteliğinde olan bu çalışmada, 12 aylık periyotta (Ocak-Aralık 2016) pediatrik ayaktan hastalara solunum yolu enfeksiyonu tanısı ile oral klaritromisin yazılan reçeteler İstanbul ili Üsküdar ilçesinde faaliyet gösteren ve çalışmaya katılmayı kabul eden, üç serbest eczaneden toplanarak müstahzar isim ve sayıları ile hasta demografik verileri (yaş, cinsiyet) kayıt edildi. PDDI’lar etkin madde bazında RxMediaPharma® programı ile tespit analiz edildi. Bulgular: On iki aylık periyotta 52 farklı hekim tarafından 266 adet müstahzarın reçetelendiği 100 adet reçete toplanmış olup, reçete başına ortalama müstahzar sayısı 2,66±1,11 idi. Tespit edilen 16 PDDI’nın 5’i klaritromisin (%31,25) ve 11 tanesi klaritromisin dışı (%68,75) idi. PDDI’lar şiddet bazında kategorize edildiğinde, toplam 16 etkileşimden 10 tanesi (%62,5) yüksek, 2 tanesi (%12,5) orta ve 4’ü (%25) düşük idi. Klaritromisin etkileşimleri ise: Lidokain ile orta; metronidazol ve sultamisin (ampisilin/sulbaktam) ile ise minör kategorisinde idi. Sonuç: Hızlı erişim imkanı sağlayan bilgisayarlı ilaç etkileşimi kontrol sistemleri tek başlarına yeterli olmamakla beraber PDDI’ların önlenmesinde sağlık personeline yardımcı olabilir. Bu sistemlerin serbest eczanelerde kullanımı ilacın hastaya verilmesi esnasında yaşanacak olan DDI’ların önlenmesinde oldukça önem taşımaktadır.

🔖

Cite This Article

BERK, B., MACİT, Ç., TANER, N., ŞİMŞEK, A., MERCANOĞLU, G. (2022). The Importance of Computerized Drug Interaction Checker Programs Used in Community Pharmacies to Avoid Potential Drug Interactions: A Preliminary Study with Clarithromycin. İstanbul Medical Journal, Cilt: 20 - Sayı: 1, 67–71. https://ajindex.com/articles/552323

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Wyles H, Rehman HU. Inappropriate polypharmacy in the elderly. Eur J Intern Med 2005; 16: 311-3
  2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The Lancet 2000; 35: 1255-9
  3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9
  4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
  5. Dirim MM, Mousavi S, Tabrizian K, Afshari A, Ashrafi MH. Potential drugdrug interactions in prescriptions dispensed in community and hospital pharmacies in East of Iran. J Res Pharm Pract 2014; 3: 104-7
  6. Ansari J. Drug Interaction and Pharmacist. J Young Pharm 2010; 2: 326-31
  7. Abarca J, Malone D, Skrepnek G, Rehfeld R, Murphy J, Grizzle AJ, et al. Community pharmacy managers’ perception of computerized drug-drug interaction alerts. J Am Pharm Assoc 2003; 46: 148-53
  8. Aagaard L, Christensen A, Hansen EH. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. Br J Clin Pharmacol 2010; 70: 481-91
  9. Harper MB, Longhurst CA, McGuire TL, Tarrago R, Patterson A. Core Drug-drug interaction alerts for inclusion in pediatric electronic health records with computerized prescriber order entry. J Patient Saf 2014; 10: 59-63
  10. King SM. Claritromycin for children. Can J Infect Dis 1995; 6: 69-70
  11. GEMAŞ AŞ. RxMediaPharma® İnteraktif İlaç Bilgi Kaynağı, https://www. eczanet.com/rxmediapharma (accessed January 1, 2017)
  12. Benavides S, Huynh D, Brias L. Approach to the pediatric prescription in a community pharmacy. J Pediatr Pharmacol Ther 2011; 16: 298-307
  13. Clavenna A, Bonatti M. Differences in antibiotic prescribing in pediatric outpatients. Arch Disease Child 2011; 96: 590-5
  14. Reimche L, Forster AJ, van Walraven C. Incidence and contributors to potential drug-drug interactions in hospitalized patients. J Clin Pharmacol 2011; 51: 1043-50
  15. Straubhaar B, Krahenbuhl S, Schlienger RG. The prevalence of potential drugdrug interactions in patients with heart failure at hospital discharge. Drug Saf 2006; 29: 79-90
  16. Kliegman B, Nelson J.Textbook of Pediatrics, 17th ed., Elsevier, Philadelphia, USA, 2003
  17. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillan